ID   KIT_HUMAN               Reviewed;         976 AA.
AC   P10721; B5A956; D5LXN2; D5M931; F5H8F8; Q6IQ28; Q99662; Q9UM99;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   12-OCT-2022, entry version 249.
DE   RecName: Full=Mast/stem cell growth factor receptor Kit;
DE            Short=SCFR;
DE            EC=2.7.10.1;
DE   AltName: Full=Piebald trait protein;
DE            Short=PBT;
DE   AltName: Full=Proto-oncogene c-Kit;
DE   AltName: Full=Tyrosine-protein kinase Kit;
DE   AltName: Full=p145 c-kit;
DE   AltName: Full=v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;
DE   AltName: CD_antigen=CD117;
DE   Flags: Precursor;
GN   Name=KIT; Synonyms=SCFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Fetal brain, and Term placenta;
RX   PubMed=2448137; DOI=10.1002/j.1460-2075.1987.tb02655.x;
RA   Yarden Y., Kuang W.-J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J.,
RA   Chen E., Schlessinger J., Francke U., Ullrich A.;
RT   "Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase
RT   for an unidentified ligand.";
RL   EMBO J. 6:3341-3351(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1 AND
RP   2).
RX   PubMed=1279499;
RA   Giebel L.B., Strunk K.M., Holmes S.A., Spritz R.A.;
RT   "Organization and nucleotide sequence of the human KIT (mast/stem cell
RT   growth factor receptor) proto-oncogene.";
RL   Oncogene 7:2207-2217(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Colon carcinoma;
RX   PubMed=7505199;
RA   Toyota M., Hinoda Y., Itoh F., Takaoka A., Imai K., Yachi A.;
RT   "Complementary DNA cloning and characterization of truncated form of c-kit
RT   in human colon carcinoma cells.";
RL   Cancer Res. 54:272-275(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9027509; DOI=10.1006/geno.1996.4482;
RA   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V., Hu W.X.,
RA   Galibert F.;
RT   "Sequence analysis of two genomic regions containing the KIT and the FMS
RT   receptor tyrosine kinase genes.";
RL   Genomics 39:216-226(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Prostate cancer;
RX   PubMed=15039213; DOI=10.1016/s0002-9440(10)63212-9;
RA   Paronetto M.P., Farini D., Sammarco I., Maturo G., Vespasiani G.,
RA   Geremia R., Rossi P., Sette C.;
RT   "Expression of a truncated form of the c-Kit tyrosine kinase receptor and
RT   activation of Src kinase in human prostatic cancer.";
RL   Am. J. Pathol. 164:1243-1251(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND
RP   INDUCTION.
RX   PubMed=20658618; DOI=10.1002/pbc.22603;
RA   Neumann I., Foell J.L., Bremer M., Volkmer I., Korholz D., Burdach S.,
RA   Staege M.S.;
RT   "Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib
RT   mesylate.";
RL   Pediatr. Blood Cancer 55:464-470(2010).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Staege M.S., Neumann I., Volkmer I.;
RT   "Sequence of KIT mRNA from all-trans retinoic acid treated neuroblastoma
RT   cell lines.";
RL   Submitted (MAR-2010) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-411 (ISOFORMS 1/2).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=7506248; DOI=10.1111/j.1349-7006.1993.tb02813.x;
RA   Yamamoto K., Tojo A., Aoki N., Shibuya M.;
RT   "Characterization of the promoter region of the human c-kit proto-
RT   oncogene.";
RL   Jpn. J. Cancer Res. 84:1136-1144(1993).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF PIK3R1; RAF1 AND MAPK1, INTERACTION WITH
RP   GRB2; PIK3R1 AND PIK3 CATALYTIC SUBUNIT, ACTIVITY REGULATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=7520444; DOI=10.1016/s0021-9258(17)31874-4;
RA   Blume-Jensen P., Ronnstrand L., Gout I., Waterfield M.D., Heldin C.H.;
RT   "Modulation of Kit/stem cell factor receptor-induced signaling by protein
RT   kinase C.";
RL   J. Biol. Chem. 269:21793-21802(1994).
RN   [14]
RP   PHOSPHORYLATION AT SER-741; SER-746; SER-821 AND SER-959, ACTIVITY
RP   REGULATION, PARTIAL PROTEIN SEQUENCE, AND MUTAGENESIS OF SER-741 AND
RP   SER-746.
RX   PubMed=7539802; DOI=10.1074/jbc.270.23.14192;
RA   Blume-Jensen P., Wernstedt C., Heldin C.H., Ronnstrand L.;
RT   "Identification of the major phosphorylation sites for protein kinase C in
RT   kit/stem cell factor receptor in vitro and in intact cells.";
RL   J. Biol. Chem. 270:14192-14200(1995).
RN   [15]
RP   INTERACTION WITH PIK3R1; MATK/CHK; FYN AND SHC1, AND PHOSPHORYLATION AT
RP   TYR-568; TYR-570 AND TYR-721.
RX   PubMed=9038210; DOI=10.1074/jbc.272.9.5915;
RA   Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.;
RT   "Direct association of Csk homologous kinase (CHK) with the
RT   diphosphorylated site Tyr568/570 of the activated c-KIT in
RT   megakaryocytes.";
RL   J. Biol. Chem. 272:5915-5920(1997).
RN   [16]
RP   INTERACTION WITH LYN.
RX   PubMed=9341198; DOI=10.1074/jbc.272.43.27450;
RA   Linnekin D., DeBerry C.S., Mou S.;
RT   "Lyn associates with the juxtamembrane region of c-Kit and is activated by
RT   stem cell factor in hematopoietic cell lines and normal progenitor cells.";
RL   J. Biol. Chem. 272:27450-27455(1997).
RN   [17]
RP   INTERACTION WITH PTPN6, AUTOPHOSPHORYLATION, AND FUNCTION IN
RP   PHOSPHORYLATION OF PTPN6.
RX   PubMed=9528781; DOI=10.1128/mcb.18.4.2089;
RA   Kozlowski M., Larose L., Lee F., Le D.M., Rottapel R., Siminovitch K.A.;
RT   "SHP-1 binds and negatively modulates the c-Kit receptor by interaction
RT   with tyrosine 569 in the c-Kit juxtamembrane domain.";
RL   Mol. Cell. Biol. 18:2089-2099(1998).
RN   [18]
RP   INTERACTION WITH GRB2 AND GRB7, PARTIAL PROTEIN SEQUENCE,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-703 AND TYR-936.
RX   PubMed=10377264; DOI=10.1042/bj3410211;
RA   Thommes K., Lennartsson J., Carlberg M., Ronnstrand L.;
RT   "Identification of Tyr-703 and Tyr-936 as the primary association sites for
RT   Grb2 and Grb7 in the c-Kit/stem cell factor receptor.";
RL   Biochem. J. 341:211-216(1999).
RN   [19]
RP   INTERACTION WITH PTPRU, AND FUNCTION IN PHOSPHORYLATION OF PTPRU.
RX   PubMed=10397721;
RA   Taniguchi Y., London R., Schinkmann K., Jiang S., Avraham H.;
RT   "The receptor protein tyrosine phosphatase, PTP-RO, is upregulated during
RT   megakaryocyte differentiation and is associated with the c-Kit receptor.";
RL   Blood 94:539-549(1999).
RN   [20]
RP   INTERACTION WITH MPDZ, CHARACTERIZATION OF VARIANT VAL-816, AND MUTAGENESIS
RP   OF LYS-623.
RX   PubMed=11018522; DOI=10.1016/s0014-5793(00)02036-6;
RA   Mancini A., Koch A., Stefan M., Niemann H., Tamura T.;
RT   "The direct association of the multiple PDZ domain containing proteins
RT   (MUPP-1) with the human c-Kit C-terminus is regulated by tyrosine kinase
RT   activity.";
RL   FEBS Lett. 482:54-58(2000).
RN   [21]
RP   INTERACTION WITH LYN; TEC AND DOK1.
RX   PubMed=11825908; DOI=10.1074/jbc.m200277200;
RA   Liang X., Wisniewski D., Strife A., Shivakrupa R., Clarkson B., Resh M.D.;
RT   "Phosphatidylinositol 3-kinase and Src family kinases are required for
RT   phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling.";
RL   J. Biol. Chem. 277:13732-13738(2002).
RN   [22]
RP   INTERACTION WITH SH2B2/APS, FUNCTION IN PHOSPHORYLATION OF SH2B2/APS, AND
RP   MUTAGENESIS OF ILE-571 AND LEU-939.
RX   PubMed=12444928; DOI=10.1042/bj20020716;
RA   Wollberg P., Lennartsson J., Gottfridsson E., Yoshimura A., Ronnstrand L.;
RT   "The adapter protein APS associates with the multifunctional docking sites
RT   Tyr-568 and Tyr-936 in c-Kit.";
RL   Biochem. J. 370:1033-1038(2003).
RN   [23]
RP   PHOSPHORYLATION AT SER-891 AND TYR-900, PARTIAL PROTEIN SEQUENCE,
RP   INTERACTION WITH CRK AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF CRK; AKT1
RP   AND MAP KINASES, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12878163; DOI=10.1016/s0014-4827(03)00206-4;
RA   Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.;
RT   "Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent
RT   phosphorylation site mediating interaction with c-Crk.";
RL   Exp. Cell Res. 288:110-118(2003).
RN   [24]
RP   FUNCTION, AND ALTERNATIVE SPLICING.
RX   PubMed=12511554; DOI=10.1074/jbc.m211726200;
RA   Voytyuk O., Lennartsson J., Mogi A., Caruana G., Courtneidge S.,
RA   Ashman L.K., Ronnstrand L.;
RT   "Src family kinases are involved in the differential signaling from two
RT   splice forms of c-Kit.";
RL   J. Biol. Chem. 278:9159-9166(2003).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-130.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [26]
RP   INTERACTION WITH FES/FPS, AND CHARACTERIZATION OF VARIANT VAL-816.
RX   PubMed=17595334; DOI=10.1182/blood-2007-02-076471;
RA   Voisset E., Lopez S., Dubreuil P., De Sepulveda P.;
RT   "The tyrosine kinase FES is an essential effector of KITD816V proliferation
RT   signal.";
RL   Blood 110:2593-2599(2007).
RN   [27]
RP   INTERACTION WITH GRB2 AND CBL, UBIQUITINATION, AND FUNCTION IN
RP   PHOSPHORYLATION OF CBL.
RX   PubMed=17904548; DOI=10.1016/j.yexcr.2007.08.021;
RA   Sun J., Pedersen M., Bengtsson S., Ronnstrand L.;
RT   "Grb2 mediates negative regulation of stem cell factor receptor/c-Kit
RT   signaling by recruitment of Cbl.";
RL   Exp. Cell Res. 313:3935-3942(2007).
RN   [28]
RP   FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS AND CELL SURVIVAL, FUNCTION IN
RP   PHOSPHORYLATION OF CBL, PHOSPHORYLATION AT TYR-568; TYR-703; TYR-721 AND
RP   TYR-936, UBIQUITINATION, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF
RP   VARIANT VAL-816.
RX   PubMed=19265199; DOI=10.1074/jbc.m808058200;
RA   Sun J., Pedersen M., Ronnstrand L.;
RT   "The D816V mutation of c-Kit circumvents a requirement for Src family
RT   kinases in c-Kit signal transduction.";
RL   J. Biol. Chem. 284:11039-11047(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-959, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [30]
RP   SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=20601678; DOI=10.1093/humrep/deq168;
RA   Muciaccia B., Sette C., Paronetto M.P., Barchi M., Pensini S.,
RA   D'Agostino A., Gandini L., Geremia R., Stefanini M., Rossi P.;
RT   "Expression of a truncated form of KIT tyrosine kinase in human spermatozoa
RT   correlates with sperm DNA integrity.";
RL   Hum. Reprod. 25:2188-2202(2010).
RN   [31]
RP   PHOSPHORYLATION AT TYR-547; TYR-553; TYR-703; TYR-721; TYR-730; TYR-823 AND
RP   TYR-900, IDENTIFICATION BY MASS SPECTROMETRY, MUTAGENESIS OF TYR-823, AND
RP   CHARACTERIZATION OF VARIANT HIS-816.
RX   PubMed=20147452; DOI=10.1093/jb/mvq015;
RA   DiNitto J.P., Deshmukh G.D., Zhang Y., Jacques S.L., Coli R., Worrall J.W.,
RA   Diehl W., English J.M., Wu J.C.;
RT   "Function of activation loop tyrosine phosphorylation in the mechanism of
RT   c-Kit auto-activation and its implication in sunitinib resistance.";
RL   J. Biochem. 147:601-609(2010).
RN   [32]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION,
RP   SUBUNIT, AND CHARACTERIZATION OF VARIANT VAL-816.
RX   PubMed=21640708; DOI=10.1016/j.bbrc.2011.05.111;
RA   Kim S.Y., Kang J.J., Lee H.H., Kang J.J., Kim B., Kim C.G., Park T.K.,
RA   Kang H.;
RT   "Mechanism of activation of human c-KIT kinase by internal tandem
RT   duplications of the juxtamembrane domain and point mutations at aspartic
RT   acid 816.";
RL   Biochem. Biophys. Res. Commun. 410:224-228(2011).
RN   [33]
RP   FUNCTION IN ACTIVATION AND PHOSPHORYLATION OF STAT1; STAT3; STAT5A AND
RP   STAT5B.
RX   PubMed=21135090; DOI=10.1074/jbc.m110.182642;
RA   Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P.;
RT   "Mechanisms of STAT protein activation by oncogenic KIT mutants in
RT   neoplastic mast cells.";
RL   J. Biol. Chem. 286:5956-5966(2011).
RN   [34]
RP   REVIEW.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [35]
RP   REVIEW ON KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [36]
RP   REVIEW.
RX   PubMed=15625120; DOI=10.1634/stemcells.2004-0117;
RA   Lennartsson J., Jelacic T., Linnekin D., Shivakrupa R.;
RT   "Normal and oncogenic forms of the receptor tyrosine kinase kit.";
RL   Stem Cells 23:16-43(2005).
RN   [37]
RP   REVIEW.
RX   PubMed=18381929; DOI=10.1158/1078-0432.ccr-07-5134;
RA   Kent D., Copley M., Benz C., Dykstra B., Bowie M., Eaves C.;
RT   "Regulation of hematopoietic stem cells by the steel factor/KIT signaling
RT   pathway.";
RL   Clin. Cancer Res. 14:1926-1930(2008).
RN   [38]
RP   REVIEW.
RX   PubMed=21057534; DOI=10.1038/onc.2010.494;
RA   Pittoni P., Piconese S., Tripodo C., Colombo M.P.;
RT   "Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary
RT   off-target of tyrosine kinase inhibitors.";
RL   Oncogene 30:757-769(2011).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 549-931 IN COMPLEX WITH ADP AND
RP   MAGNESIUM IONS, SUBUNIT, PHOSPHORYLATION AT TYR-568 AND TYR-570, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12824176; DOI=10.1074/jbc.c300186200;
RA   Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C.,
RA   Nowakowski J., Kassel D.B., Cronin C.N., McRee D.E.;
RT   "Structure of a c-kit product complex reveals the basis for kinase
RT   transactivation.";
RL   J. Biol. Chem. 278:31461-31464(2003).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 565-935 IN COMPLEXES WITH
RP   INHIBITOR IMATINIB AND PHOSPHATE, AND ACTIVITY REGULATION.
RX   PubMed=15123710; DOI=10.1074/jbc.m403319200;
RA   Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L.,
RA   Scheibe D.N., Snell G.P., Zou H., Sang B.C., Wilson K.P.;
RT   "Structural basis for the autoinhibition and STI-571 inhibition of c-Kit
RT   tyrosine kinase.";
RL   J. Biol. Chem. 279:31655-31663(2004).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 1-519 IN COMPLEX WITH KITLG/SCF,
RP   INTERACTION WITH KITLG/SCF, SUBUNIT, DISULFIDE BONDS, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF ARG-381 AND GLU-386, AND GLYCOSYLATION
RP   AT ASN-130; ASN-283; ASN-293; ASN-300; ASN-320; ASN-352 AND ASN-367.
RX   PubMed=17662946; DOI=10.1016/j.cell.2007.05.055;
RA   Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I., Schlessinger J.;
RT   "Structural basis for activation of the receptor tyrosine kinase KIT by
RT   stem cell factor.";
RL   Cell 130:323-334(2007).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 544-935 IN COMPLEX WITH SUNITINIB,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, CHARACTERIZATION OF VARIANTS
RP   HIS-816 AND VAL-816, AND ACTIVITY REGULATION.
RX   PubMed=19164557; DOI=10.1073/pnas.0812413106;
RA   Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W.,
RA   DiNitto J.P., English J.M., Greig M.J., He Y.A., Jacques S.L., Lunney E.A.,
RA   McTigue M., Molina D., Quenzer T., Wells P.A., Yu X., Zhang Y., Zou A.,
RA   Emmett M.R., Marshall A.G., Zhang H.M., Demetri G.D.;
RT   "KIT kinase mutants show unique mechanisms of drug resistance to imatinib
RT   and sunitinib in gastrointestinal stromal tumor patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:1542-1547(2009).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 564-574 IN COMPLEX WITH SOCS6,
RP   AND PHOSPHORYLATION AT TYR-568.
RX   PubMed=21030588; DOI=10.1074/jbc.m110.173526;
RA   Zadjali F., Pike A.C., Vesterlund M., Sun J., Wu C., Li S.S.,
RA   Ronnstrand L., Knapp S., Bullock A.N., Flores-Morales A.;
RT   "Structural basis for c-KIT inhibition by the suppressor of cytokine
RT   signaling 6 (SOCS6) ubiquitin ligase.";
RL   J. Biol. Chem. 286:480-490(2011).
RN   [44]
RP   VARIANT PBT LYS-583.
RX   PubMed=1376329; DOI=10.1172/jci115772;
RA   Fleischman R.A.;
RT   "Human piebald trait resulting from a dominant negative mutant allele of
RT   the c-kit membrane receptor gene.";
RL   J. Clin. Invest. 89:1713-1717(1992).
RN   [45]
RP   VARIANT PBT LEU-584.
RX   PubMed=1370874;
RA   Spritz R.A., Giebel L.B., Holmes S.A.;
RT   "Dominant negative and loss of function mutations of the c-kit (mast/stem
RT   cell growth factor receptor) proto-oncogene in human piebaldism.";
RL   Am. J. Hum. Genet. 50:261-269(1992).
RN   [46]
RP   VARIANT PBT ARG-664.
RX   PubMed=1717985; DOI=10.1073/pnas.88.19.8696;
RA   Giebel L.B., Spritz R.A.;
RT   "Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene
RT   in human piebaldism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8696-8699(1991).
RN   [47]
RP   VARIANT MAST CELL LEUKEMIA VAL-816.
RX   PubMed=7691885; DOI=10.1172/jci116761;
RA   Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U.,
RA   Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y., Matsuzawa Y.,
RA   Kitamura Y., Kanakura Y.;
RT   "Identification of mutations in the coding sequence of the proto-oncogene
RT   c-kit in a human mast cell leukemia cell line causing ligand-independent
RT   activation of c-kit product.";
RL   J. Clin. Invest. 92:1736-1744(1993).
RN   [48]
RP   VARIANTS PBT GLY-791 AND VAL-812.
RX   PubMed=7687267; DOI=10.1111/1523-1747.ep12358440;
RA   Spritz R.A., Holmes S.A., Itin P., Kuester W.;
RT   "Novel mutations of the KIT (mast/stem cell growth factor receptor) proto-
RT   oncogene in human piebaldism.";
RL   J. Invest. Dermatol. 101:22-25(1993).
RN   [49]
RP   VARIANT PBT 893-GLU--PRO-896 DEL.
RX   PubMed=8680409; DOI=10.1002/humu.1380060409;
RA   Riva P., Milani N., Gandolfi P., Larizza L.;
RT   "A 12-bp deletion (7818del12) in the c-kit protooncogene in a large Italian
RT   kindred with piebaldism.";
RL   Hum. Mutat. 6:343-345(1995).
RN   [50]
RP   VARIANT MAST CELL DISEASE GLY-820.
RX   PubMed=9029028; DOI=10.1046/j.1365-2141.1997.d01-2042.x;
RA   Pignon J.-M., Giraudier S., Duquesnoy P., Jouault H., Imbert M.,
RA   Vainchenker W., Vernant J.-P., Tulliez M.;
RT   "A new c-kit mutation in a case of aggressive mast cell disease.";
RL   Br. J. Haematol. 96:374-376(1997).
RN   [51]
RP   VARIANT PBT GLY-796.
RX   PubMed=9450866;
RX   DOI=10.1002/(sici)1096-8628(19980106)75:1<101::aid-ajmg20>3.0.co;2-p;
RA   Spritz R.A., Beighton P.;
RT   "Piebaldism with deafness: molecular evidence for an expanded syndrome.";
RL   Am. J. Med. Genet. 75:101-103(1998).
RN   [52]
RP   VARIANT ACUTE MYELOID LEUKEMIA TYR-816.
RX   PubMed=9657776;
RA   Beghini A., Larizza L., Cairoli R., Morra E.;
RT   "c-kit activating mutations and mast cell proliferation in human
RT   leukemia.";
RL   Blood 92:701-702(1998).
RN   [53]
RP   VARIANT PBT PRO-847.
RX   PubMed=9699740; DOI=10.1046/j.1523-1747.1998.00269.x;
RA   Nomura K., Hatayama I., Narita T., Kaneko T., Shiraishi M.;
RT   "A novel KIT gene missense mutation in a Japanese family with piebaldism.";
RL   J. Invest. Dermatol. 111:337-338(1998).
RN   [54]
RP   VARIANT GIST VAL-559 DEL.
RX   PubMed=9697690; DOI=10.1038/1209;
RA   Nishida T., Hirota S., Taniguchi M., Hashimoto K., Isozaki K., Nakamura H.,
RA   Kanakura Y., Tanaka T., Takabayashi A., Matsuda H., Kitamura Y.;
RT   "Familial gastrointestinal stromal tumours with germline mutation of the
RT   KIT gene.";
RL   Nat. Genet. 19:323-324(1998).
RN   [55]
RP   VARIANTS GIST ILE-550; 550-LYS--LYS-558 DEL; 551-PRO--VAL-555 DEL; ASP-559
RP   AND 559-VAL-VAL-560 DEL.
RX   PubMed=9438854; DOI=10.1126/science.279.5350.577;
RA   Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S.,
RA   Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G.,
RA   Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y.;
RT   "Gain-of-function mutations of c-kit in human gastrointestinal stromal
RT   tumors.";
RL   Science 279:577-580(1998).
RN   [56]
RP   VARIANT HIS-816, AND CHARACTERIZATION OF VARIANT HIS-816.
RX   PubMed=10362788; DOI=10.1016/s0002-9440(10)65419-3;
RA   Tian Q., Frierson H.F. Jr., Krystal G.W., Moskaluk C.A.;
RT   "Activating c-kit gene mutations in human germ cell tumors.";
RL   Am. J. Pathol. 154:1643-1647(1999).
RN   [57]
RP   VARIANTS MASTSYS VAL-816 AND TYR-816, VARIANTS MASTC PHE-816 AND LYS-839,
RP   CHARACTERIZATION OF VARIANTS MASTSYS VAL-816 AND TYR-816, CHARACTERIZATION
RP   OF VARIANTS MASTC PHE-816 AND LYS-839, AND INVOLVEMENT IN MASTSYS AND
RP   MASTC.
RX   PubMed=9990072; DOI=10.1073/pnas.96.4.1609;
RA   Longley B.J. Jr., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.-Z.,
RA   Heitjan D., Ma Y.;
RT   "Activating and dominant inactivating c-KIT catalytic domain mutations in
RT   distinct clinical forms of human mastocytosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1609-1614(1999).
RN   [58]
RP   VARIANTS PBT CYS-584; ARG-601 AND PRO-656.
RX   PubMed=11074500;
RX   DOI=10.1002/1096-8628(20001106)95:1<79::aid-ajmg16>3.0.co;2-4;
RA   Syrris P., Malik N.M., Murday V.A., Patton M.A., Carter N.D., Hughes H.E.,
RA   Metcalfe K.;
RT   "Three novel mutations of the proto-oncogene KIT cause human piebaldism.";
RL   Am. J. Med. Genet. 95:79-81(2000).
RN   [59]
RP   VARIANT GIST ALA-559.
RX   PubMed=11505412;
RX   DOI=10.1002/1097-0142(20010801)92:3<657::aid-cncr1367>3.0.co;2-d;
RA   Beghini A., Tibiletti M.G., Roversi G., Chiaravalli A.M., Serio G.,
RA   Capella C., Larizza L.;
RT   "Germline mutation in the juxtamembrane domain of the kit gene in a family
RT   with gastrointestinal stromal tumors and urticaria pigmentosa.";
RL   Cancer 92:657-662(2001).
RN   [60]
RP   VARIANT MASTC ASP-533, AND INVOLVEMENT IN MASTC.
RX   PubMed=15173254; DOI=10.1136/jmg.2003.015156;
RA   Tang X., Boxer M., Drummond A., Ogston P., Hodgins M., Burden A.D.;
RT   "A germline mutation in KIT in familial diffuse cutaneous mastocytosis.";
RL   J. Med. Genet. 41:E88-E88(2004).
RN   [61]
RP   VARIANT GIST 550-LYS--LYS-558 DEL.
RX   PubMed=15824741; DOI=10.1038/sj.onc.1208587;
RA   Chen L.L., Sabripour M., Wu E.F., Prieto V.G., Fuller G.N., Frazier M.L.;
RT   "A mutation-created novel intra-exonic pre-mRNA splice site causes
RT   constitutive activation of KIT in human gastrointestinal stromal tumors.";
RL   Oncogene 24:4271-4280(2005).
RN   [62]
RP   VARIANTS TYR-816; LYS-822 AND PRO-829.
RX   PubMed=16175573; DOI=10.1002/gcc.20265;
RA   Bignell G., Smith R., Hunter C., Stephens P., Davies H., Greenman C.,
RA   Teague J., Butler A., Edkins S., Stevens C., O'meara S., Parker A.,
RA   Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J.,
RA   Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K.,
RA   Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R.,
RA   Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A.,
RA   Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S.,
RA   Yates A., Gillis A.J.M., Stoop H.J., van Gurp R.J.H.L.M., Oosterhuis J.W.,
RA   Looijenga L.H.J., Futreal P.A., Wooster R., Stratton M.R.;
RT   "Sequence analysis of the protein kinase gene family in human testicular
RT   germ-cell tumors of adolescents and adults.";
RL   Genes Chromosomes Cancer 45:42-46(2006).
RN   [63]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-532; LEU-541; SER-691; ASN-715;
RP   ASN-737; TRP-804; TYR-816; LYS-822 AND PRO-829.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [64]
RP   VARIANT LEU-541, VARIANTS MASTC ILE-816; TYR-816 AND VAL-816, AND
RP   CHARACTERIZATION OF VARIANTS MASTC ILE-816; TYR-816 AND VAL-816.
RX   PubMed=19865100; DOI=10.1038/jid.2009.281;
RA   Bodemer C., Hermine O., Palmerini F., Yang Y., Grandpeix-Guyodo C.,
RA   Leventhal P.S., Hadj-Rabia S., Nasca L., Georgin-Lavialle S.,
RA   Cohen-Akenine A., Launay J.M., Barete S., Feger F., Arock M., Catteau B.,
RA   Sans B., Stalder J.F., Skowron F., Thomas L., Lorette G., Plantin P.,
RA   Bordigoni P., Lortholary O., de Prost Y., Moussy A., Sobol H., Dubreuil P.;
RT   "Pediatric mastocytosis is a clonal disease associated with D816V and other
RT   activating c-KIT mutations.";
RL   J. Invest. Dermatol. 130:804-815(2010).
RN   [65]
RP   VARIANT MASTC ILE-822, CHARACTERIZATION OF VARIANT MASTC ILE-822, AND
RP   INVOLVEMENT IN MASTC.
RX   PubMed=21689725; DOI=10.1016/j.exphem.2011.05.009;
RA   Wasag B., Niedoszytko M., Piskorz A., Lange M., Renke J., Jassem E.,
RA   Biernat W., Debiec-Rychter M., Limon J.;
RT   "Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.";
RL   Exp. Hematol. 39:859-865(2011).
RN   [66]
RP   VARIANT MASTC CYS-451, AND INVOLVEMENT IN MASTC.
RX   PubMed=24289326; DOI=10.1111/ced.12225;
RA   Wang H.J., Lin Z.M., Zhang J., Yin J.H., Yang Y.;
RT   "A new germline mutation in KIT associated with diffuse cutaneous
RT   mastocytosis in a Chinese family.";
RL   Clin. Exp. Dermatol. 39:146-149(2014).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor
CC       for the cytokine KITLG/SCF and plays an essential role in the
CC       regulation of cell survival and proliferation, hematopoiesis, stem cell
CC       maintenance, gametogenesis, mast cell development, migration and
CC       function, and in melanogenesis. In response to KITLG/SCF binding, KIT
CC       can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1,
CC       SH2B2/APS and CBL. Activates the AKT1 signaling pathway by
CC       phosphorylation of PIK3R1, the regulatory subunit of
CC       phosphatidylinositol 3-kinase. Activated KIT also transmits signals via
CC       GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or
CC       MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3,
CC       STAT5A and STAT5B. Activation of PLCG1 leads to the production of the
CC       cellular signaling molecules diacylglycerol and inositol 1,4,5-
CC       trisphosphate. KIT signaling is modulated by protein phosphatases, and
CC       by rapid internalization and degradation of the receptor. Activated KIT
CC       promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and
CC       PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and
CC       STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II),
CC       LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1.
CC       {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12444928,
CC       ECO:0000269|PubMed:12511554, ECO:0000269|PubMed:12878163,
CC       ECO:0000269|PubMed:17904548, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:9528781}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:17662946, ECO:0000269|PubMed:19164557,
CC         ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:2448137};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. KITLG/SCF binding leads to dimerization and activation
CC       by autophosphorylation on tyrosine residues. Activity is down-regulated
CC       by PRKCA-mediated phosphorylation on serine residues. Inhibited by
CC       imatinib/STI-571 (Gleevec) and sunitinib; these compounds maintain the
CC       kinase in an inactive conformation. {ECO:0000269|PubMed:15123710,
CC       ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:7539802}.
CC   -!- SUBUNIT: Monomer in the absence of bound KITLG/SCF. Homodimer in the
CC       presence of bound KITLG/SCF, forming a heterotetramer with two
CC       KITLG/SCF molecules. Interacts (via phosphorylated tyrosine residues)
CC       with the adapter proteins GRB2 and GRB7 (via SH2 domain), and
CC       SH2B2/APS. Interacts (via C-terminus) with MPDZ (via the tenth PDZ
CC       domain). Interacts (via phosphorylated tyrosine residues) with PIK3R1
CC       and PIK3 catalytic subunit. Interacts (via phosphorylated tyrosine)
CC       with CRK (isoform Crk-II), FYN, SHC1 and MATK/CHK (via SH2 domain).
CC       Interacts with LYN and FES/FPS. Interacts (via phosphorylated tyrosine
CC       residues) with the protein phosphatases PTPN6/SHP-1 (via SH2 domain),
CC       PTPN11/SHP-2 (via SH2 domain) and PTPRU. Interacts with PLCG1.
CC       Interacts with DOK1 and TEC. Interacts (KITLG/SCF-bound) with IL1RL1.
CC       Interacts with IL1RAP (independent of stimulation with KITLG/SCF). A
CC       mast cell-specific KITLG/SCF-induced interleukin-33 signaling complex
CC       contains IL1RL1, IL1RAP, KIT and MYD88. {ECO:0000250|UniProtKB:P05532,
CC       ECO:0000269|PubMed:10377264, ECO:0000269|PubMed:10397721,
CC       ECO:0000269|PubMed:11018522, ECO:0000269|PubMed:11825908,
CC       ECO:0000269|PubMed:12444928, ECO:0000269|PubMed:12824176,
CC       ECO:0000269|PubMed:12878163, ECO:0000269|PubMed:17595334,
CC       ECO:0000269|PubMed:17662946, ECO:0000269|PubMed:17904548,
CC       ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21030588,
CC       ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7520444,
CC       ECO:0000269|PubMed:9038210, ECO:0000269|PubMed:9341198,
CC       ECO:0000269|PubMed:9528781}.
CC   -!- INTERACTION:
CC       P10721; P00519: ABL1; NbExp=2; IntAct=EBI-1379503, EBI-375543;
CC       P10721; P42684: ABL2; NbExp=2; IntAct=EBI-1379503, EBI-1102694;
CC       P10721; O75815: BCAR3; NbExp=3; IntAct=EBI-1379503, EBI-702336;
CC       P10721; P51451: BLK; NbExp=5; IntAct=EBI-1379503, EBI-2105445;
CC       P10721; Q8WV28: BLNK; NbExp=2; IntAct=EBI-1379503, EBI-2623522;
CC       P10721; P46108: CRK; NbExp=4; IntAct=EBI-1379503, EBI-886;
CC       P10721; P07332: FES; NbExp=2; IntAct=EBI-1379503, EBI-1055635;
CC       P10721; P09769: FGR; NbExp=2; IntAct=EBI-1379503, EBI-1383732;
CC       P10721; O75791: GRAP2; NbExp=2; IntAct=EBI-1379503, EBI-740418;
CC       P10721; P62993: GRB2; NbExp=6; IntAct=EBI-1379503, EBI-401755;
CC       P10721; Q14451: GRB7; NbExp=4; IntAct=EBI-1379503, EBI-970191;
CC       P10721; P08631: HCK; NbExp=2; IntAct=EBI-1379503, EBI-346340;
CC       P10721; Q96JZ2: HSH2D; NbExp=5; IntAct=EBI-1379503, EBI-3919324;
CC       P10721; P21583: KITLG; NbExp=2; IntAct=EBI-1379503, EBI-1379527;
CC       P10721; P06239: LCK; NbExp=8; IntAct=EBI-1379503, EBI-1348;
CC       P10721; P07948: LYN; NbExp=7; IntAct=EBI-1379503, EBI-79452;
CC       P10721; P16333: NCK1; NbExp=3; IntAct=EBI-1379503, EBI-389883;
CC       P10721; O43639: NCK2; NbExp=2; IntAct=EBI-1379503, EBI-713635;
CC       P10721; P27986: PIK3R1; NbExp=19; IntAct=EBI-1379503, EBI-79464;
CC       P10721; O00459: PIK3R2; NbExp=19; IntAct=EBI-1379503, EBI-346930;
CC       P10721; Q92569: PIK3R3; NbExp=31; IntAct=EBI-1379503, EBI-79893;
CC       P10721; P19174: PLCG1; NbExp=31; IntAct=EBI-1379503, EBI-79387;
CC       P10721; P16885: PLCG2; NbExp=8; IntAct=EBI-1379503, EBI-617403;
CC       P10721; Q13882: PTK6; NbExp=4; IntAct=EBI-1379503, EBI-1383632;
CC       P10721; Q06124: PTPN11; NbExp=29; IntAct=EBI-1379503, EBI-297779;
CC       P10721; Q92729: PTPRU; NbExp=2; IntAct=EBI-1379503, EBI-7052301;
CC       P10721; P20936: RASA1; NbExp=16; IntAct=EBI-1379503, EBI-1026476;
CC       P10721; Q9UQQ2: SH2B3; NbExp=2; IntAct=EBI-1379503, EBI-7879749;
CC       P10721; O14796: SH2D1B; NbExp=8; IntAct=EBI-1379503, EBI-3923013;
CC       P10721; Q9NP31: SH2D2A; NbExp=10; IntAct=EBI-1379503, EBI-490630;
CC       P10721; Q8N5H7: SH2D3C; NbExp=4; IntAct=EBI-1379503, EBI-745980;
CC       P10721; P78314: SH3BP2; NbExp=3; IntAct=EBI-1379503, EBI-727062;
CC       P10721; Q15464: SHB; NbExp=2; IntAct=EBI-1379503, EBI-4402156;
CC       P10721; P29353: SHC1; NbExp=8; IntAct=EBI-1379503, EBI-78835;
CC       P10721; P98077: SHC2; NbExp=5; IntAct=EBI-1379503, EBI-7256023;
CC       P10721; Q92529: SHC3; NbExp=3; IntAct=EBI-1379503, EBI-79084;
CC       P10721; Q9H6Q3: SLA2; NbExp=2; IntAct=EBI-1379503, EBI-1222854;
CC       P10721; O14508: SOCS2; NbExp=4; IntAct=EBI-1379503, EBI-617737;
CC       P10721; O14543: SOCS3; NbExp=3; IntAct=EBI-1379503, EBI-714146;
CC       P10721; O14544: SOCS6; NbExp=12; IntAct=EBI-1379503, EBI-3929549;
CC       P10721; P12931: SRC; NbExp=5; IntAct=EBI-1379503, EBI-621482;
CC       P10721; Q9ULZ2: STAP1; NbExp=3; IntAct=EBI-1379503, EBI-6083058;
CC       P10721; Q9HBL0: TNS1; NbExp=2; IntAct=EBI-1379503, EBI-3389814;
CC       P10721; Q63HR2: TNS2; NbExp=2; IntAct=EBI-1379503, EBI-949753;
CC       P10721; Q68CZ2: TNS3; NbExp=5; IntAct=EBI-1379503, EBI-1220488;
CC       P10721; P42681: TXK; NbExp=3; IntAct=EBI-1379503, EBI-7877438;
CC       P10721; P07947: YES1; NbExp=7; IntAct=EBI-1379503, EBI-515331;
CC       P10721; P43403: ZAP70; NbExp=2; IntAct=EBI-1379503, EBI-1211276;
CC       P10721; Q8VBX6: Mpdz; Xeno; NbExp=4; IntAct=EBI-1379503, EBI-8026435;
CC       P10721; P35235: Ptpn11; Xeno; NbExp=2; IntAct=EBI-1379503, EBI-397236;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm
CC       {ECO:0000269|PubMed:20601678}. Note=Detected in the cytoplasm of
CC       spermatozoa, especially in the equatorial and subacrosomal region of
CC       the sperm head. {ECO:0000269|PubMed:20601678}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=GNNK(+), KitA(+);
CC         IsoId=P10721-1; Sequence=Displayed;
CC       Name=2; Synonyms=GNNK(-), Kit(+);
CC         IsoId=P10721-2; Sequence=VSP_038385;
CC       Name=3; Synonyms=TR-KIT {ECO:0000303|PubMed:20601678};
CC         IsoId=P10721-4; Sequence=VSP_060976;
CC   -!- TISSUE SPECIFICITY: [Isoform 3]: In testis, detected in spermatogonia
CC       in the basal layer and in interstitial Leydig cells but not in Sertoli
CC       cells or spermatocytes inside the seminiferous tubules (at protein
CC       level) (PubMed:20601678). Expression is maintained in ejaculated
CC       spermatozoa (at protein level) (PubMed:20601678).
CC       {ECO:0000269|PubMed:20601678}.
CC   -!- INDUCTION: Up-regulated by cis-retinoic acid in neuroblastoma cell
CC       lines. {ECO:0000269|PubMed:20658618}.
CC   -!- PTM: Ubiquitinated by SOCS6. KIT is rapidly ubiquitinated after
CC       autophosphorylation induced by KITLG/SCF binding, leading to
CC       internalization and degradation. {ECO:0000269|PubMed:17904548,
CC       ECO:0000269|PubMed:19265199}.
CC   -!- PTM: Autophosphorylated on tyrosine residues. KITLG/SCF binding
CC       enhances autophosphorylation. Isoform 1 shows low levels of tyrosine
CC       phosphorylation in the absence of added KITLG/SCF (in vitro). Kinase
CC       activity is down-regulated by phosphorylation on serine residues by
CC       protein kinase C family members. Phosphorylation at Tyr-568 is required
CC       for interaction with PTPN11/SHP-2, CRK (isoform Crk-II) and members of
CC       the SRC tyrosine-protein kinase family. Phosphorylation at Tyr-570 is
CC       required for interaction with PTPN6/SHP-1. Phosphorylation at Tyr-703,
CC       Tyr-823 and Tyr-936 is important for interaction with GRB2.
CC       Phosphorylation at Tyr-721 is important for interaction with PIK3R1.
CC       Phosphorylation at Tyr-823 and Tyr-936 is important for interaction
CC       with GRB7. {ECO:0000269|PubMed:10377264, ECO:0000269|PubMed:12824176,
CC       ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:20147452,
CC       ECO:0000269|PubMed:21030588, ECO:0000269|PubMed:9038210}.
CC   -!- DISEASE: Piebald trait (PBT) [MIM:172800]: Autosomal dominant genetic
CC       developmental abnormality of pigmentation characterized by congenital
CC       patches of white skin and hair that lack melanocytes.
CC       {ECO:0000269|PubMed:11074500, ECO:0000269|PubMed:1370874,
CC       ECO:0000269|PubMed:1376329, ECO:0000269|PubMed:1717985,
CC       ECO:0000269|PubMed:7687267, ECO:0000269|PubMed:8680409,
CC       ECO:0000269|PubMed:9450866, ECO:0000269|PubMed:9699740}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Gastrointestinal stromal tumor (GIST) [MIM:606764]: Common
CC       mesenchymal neoplasms arising in the gastrointestinal tract, most often
CC       in the stomach. They are histologically, immunohistochemically, and
CC       genetically different from typical leiomyomas, leiomyosarcomas, and
CC       schwannomas. Most GISTs are composed of a fairly uniform population of
CC       spindle-shaped cells. Some tumors are dominated by epithelioid cells or
CC       contain a mixture of spindle and epithelioid morphologies. Primary
CC       GISTs in the gastrointestinal tract commonly metastasize in the omentum
CC       and mesenteries, often as multiple nodules. However, primary tumors may
CC       also occur outside of the gastrointestinal tract, in other intra-
CC       abdominal locations, especially in the omentum and mesentery.
CC       {ECO:0000269|PubMed:11505412, ECO:0000269|PubMed:15824741,
CC       ECO:0000269|PubMed:9438854, ECO:0000269|PubMed:9697690}. Note=The gene
CC       represented in this entry is involved in disease pathogenesis.
CC   -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common
CC       malignancy in males representing 95% of all testicular neoplasms. TGCTs
CC       have various pathologic subtypes including: unclassified intratubular
CC       germ cell neoplasia, seminoma (including cases with
CC       syncytiotrophoblastic cells), spermatocytic seminoma, embryonal
CC       carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of
CC       acute leukemia, a cancer of the white blood cells. AML is a malignant
CC       disease of bone marrow characterized by maturational arrest of
CC       hematopoietic precursors at an early stage of development. Clonal
CC       expansion of myeloid blasts occurs in bone marrow, blood, and other
CC       tissue. Myelogenous leukemias develop from changes in cells that
CC       normally produce neutrophils, basophils, eosinophils and monocytes.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. Somatic mutations that lead to constitutive activation of
CC       KIT are detected in AML patients. These mutations fall into two
CC       classes, the most common being in-frame internal tandem duplications of
CC       variable length in the juxtamembrane region that disrupt the normal
CC       regulation of the kinase activity. Likewise, point mutations in the
CC       kinase domain can result in a constitutively activated kinase.
CC   -!- DISEASE: Mastocytosis, cutaneous (MASTC) [MIM:154800]: A form of
CC       mastocytosis, a heterogeneous group of disorders associated with
CC       abnormal proliferation and accumulation of mast cells in various
CC       tissues, especially in the skin and hematopoietic organs. MASTC is an
CC       autosomal dominant form characterized by macules, papules, nodules, or
CC       diffuse infiltration of the skin, often associated with localized
CC       hyperpigmentation. Gentle rubbing of the lesions induces histamine
CC       release from mechanically activated mast cells, causing local wheals,
CC       erythema, and often pruritus, a phenomenon termed Darier sign.
CC       {ECO:0000269|PubMed:15173254, ECO:0000269|PubMed:19865100,
CC       ECO:0000269|PubMed:21689725, ECO:0000269|PubMed:24289326,
CC       ECO:0000269|PubMed:9990072}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mastocytosis, systemic (MASTSYS) [MIM:154800]: A severe form
CC       of mastocytosis characterized by abnormal proliferation and
CC       accumulation of mast cells in several organs, resulting in a systemic
CC       disease that may affect bone, gastrointestinal tract, lymphatics,
CC       spleen, and liver. In some cases, it is associated with a clonal
CC       hematologic non-mast-cell lineage disease, such as a myelodysplastic or
CC       myeloproliferative disorder. It can also lead to mast cell leukemia,
CC       which carries a high risk of mortality. {ECO:0000269|PubMed:9990072}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: Numerous proteins are phosphorylated in response to KIT
CC       signaling, but it is not evident to determine which are directly
CC       phosphorylated by KIT under in vivo conditions.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=ACF47630.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/KITID127.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD117 entry;
CC       URL="https://en.wikipedia.org/wiki/CD117";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=two's company - Issue 163 of
CC       August 2014;
CC       URL="https://web.expasy.org/spotlight/back_issues/163/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X06182; CAA29548.1; -; mRNA.
DR   EMBL; X69301; CAA49159.1; -; Genomic_DNA.
DR   EMBL; X69302; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69303; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69304; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69305; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69306; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69307; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69308; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69309; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69310; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69311; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69312; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69313; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69314; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69315; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69316; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; U63834; AAC50968.1; -; Genomic_DNA.
DR   EMBL; U63834; AAC50969.1; -; Genomic_DNA.
DR   EMBL; GU983671; ADF36702.1; -; mRNA.
DR   EMBL; HM015525; ADF50068.1; -; mRNA.
DR   EMBL; HM015526; ADF50069.1; -; mRNA.
DR   EMBL; AK304031; BAG64945.1; -; mRNA.
DR   EMBL; AC006552; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092545; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC071593; AAH71593.1; -; mRNA.
DR   EMBL; EU826594; ACF47630.1; ALT_SEQ; mRNA.
DR   EMBL; S67773; AAB29529.1; -; Genomic_DNA.
DR   CCDS; CCDS3496.1; -. [P10721-1]
DR   CCDS; CCDS47058.1; -. [P10721-2]
DR   PIR; S01426; TVHUKT.
DR   RefSeq; NP_000213.1; NM_000222.2. [P10721-1]
DR   RefSeq; NP_001087241.1; NM_001093772.1. [P10721-2]
DR   PDB; 1PKG; X-ray; 2.90 A; A/B=549-935.
DR   PDB; 1T45; X-ray; 1.90 A; A=547-693, A=754-935.
DR   PDB; 1T46; X-ray; 1.60 A; A=565-693, A=754-935.
DR   PDB; 2E9W; X-ray; 3.50 A; A/B=26-514.
DR   PDB; 2EC8; X-ray; 3.00 A; A=1-519.
DR   PDB; 2IUH; X-ray; 2.00 A; B=718-728.
DR   PDB; 2VIF; X-ray; 1.45 A; P=564-574.
DR   PDB; 3G0E; X-ray; 1.60 A; A=544-693, A=754-935.
DR   PDB; 3G0F; X-ray; 2.60 A; A/B=544-693, A/B=754-935.
DR   PDB; 4HVS; X-ray; 1.90 A; A=551-934.
DR   PDB; 4K94; X-ray; 2.40 A; C=308-518.
DR   PDB; 4K9E; X-ray; 2.70 A; C=308-518.
DR   PDB; 4PGZ; X-ray; 2.40 A; A/B/C=308-518.
DR   PDB; 4U0I; X-ray; 2.00 A; A=563-693, A=754-935.
DR   PDB; 6GQJ; X-ray; 2.33 A; A/B=551-933.
DR   PDB; 6GQK; X-ray; 2.31 A; A/B=551-687, A/B=771-934.
DR   PDB; 6GQL; X-ray; 2.01 A; A/B=551-934.
DR   PDB; 6GQM; X-ray; 2.00 A; A/B=551-934.
DR   PDB; 6HH1; X-ray; 2.25 A; A=565-702, A=802-929.
DR   PDB; 6ITT; X-ray; 2.10 A; A/B=547-693, A/B=754-935.
DR   PDB; 6ITV; X-ray; 1.88 A; A=547-693, A=754-935.
DR   PDB; 6KLA; X-ray; 2.11 A; A=547-693, A=754-935.
DR   PDB; 6MOB; X-ray; 1.80 A; A=566-693, A=754-935.
DR   PDB; 6XV9; X-ray; 3.38 A; A/B=551-687, A/B=766-934.
DR   PDB; 6XVA; X-ray; 2.30 A; A/B=551-687, A/B=766-934.
DR   PDB; 6XVB; X-ray; 2.15 A; A/B=551-687, A/B=766-934.
DR   PDB; 7KHG; X-ray; 2.15 A; A=545-934.
DR   PDB; 7KHJ; X-ray; 2.80 A; A/B=545-934.
DR   PDB; 7KHK; X-ray; 2.34 A; A/B=545-934.
DR   PDBsum; 1PKG; -.
DR   PDBsum; 1T45; -.
DR   PDBsum; 1T46; -.
DR   PDBsum; 2E9W; -.
DR   PDBsum; 2EC8; -.
DR   PDBsum; 2IUH; -.
DR   PDBsum; 2VIF; -.
DR   PDBsum; 3G0E; -.
DR   PDBsum; 3G0F; -.
DR   PDBsum; 4HVS; -.
DR   PDBsum; 4K94; -.
DR   PDBsum; 4K9E; -.
DR   PDBsum; 4PGZ; -.
DR   PDBsum; 4U0I; -.
DR   PDBsum; 6GQJ; -.
DR   PDBsum; 6GQK; -.
DR   PDBsum; 6GQL; -.
DR   PDBsum; 6GQM; -.
DR   PDBsum; 6HH1; -.
DR   PDBsum; 6ITT; -.
DR   PDBsum; 6ITV; -.
DR   PDBsum; 6KLA; -.
DR   PDBsum; 6MOB; -.
DR   PDBsum; 6XV9; -.
DR   PDBsum; 6XVA; -.
DR   PDBsum; 6XVB; -.
DR   PDBsum; 7KHG; -.
DR   PDBsum; 7KHJ; -.
DR   PDBsum; 7KHK; -.
DR   AlphaFoldDB; P10721; -.
DR   SMR; P10721; -.
DR   BioGRID; 110015; 103.
DR   CORUM; P10721; -.
DR   DIP; DIP-1055N; -.
DR   IntAct; P10721; 97.
DR   MINT; P10721; -.
DR   STRING; 9606.ENSP00000288135; -.
DR   BindingDB; P10721; -.
DR   ChEMBL; CHEMBL1936; -.
DR   DrugBank; DB12742; Amuvatinib.
DR   DrugBank; DB09103; Ancestim.
DR   DrugBank; DB15233; Avapritinib.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12147; Erdafitinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB06080; Linifanib.
DR   DrugBank; DB06595; Midostaurin.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB05913; OSI-930.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB12978; Pexidartinib.
DR   DrugBank; DB01962; Phosphonotyrosine.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB14840; Ripretinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugBank; DB05146; XL820.
DR   DrugCentral; P10721; -.
DR   GuidetoPHARMACOLOGY; 1805; -.
DR   CarbonylDB; P10721; -.
DR   GlyConnect; 1492; 3 N-Linked glycans (2 sites).
DR   GlyGen; P10721; 10 sites, 1 Asn glycan (1 site), 3 N-linked glycans (2 sites).
DR   iPTMnet; P10721; -.
DR   PhosphoSitePlus; P10721; -.
DR   BioMuta; KIT; -.
DR   DMDM; 125472; -.
DR   EPD; P10721; -.
DR   jPOST; P10721; -.
DR   MassIVE; P10721; -.
DR   MaxQB; P10721; -.
DR   PaxDb; P10721; -.
DR   PeptideAtlas; P10721; -.
DR   PRIDE; P10721; -.
DR   ProteomicsDB; 52640; -. [P10721-1]
DR   ProteomicsDB; 52641; -. [P10721-2]
DR   ABCD; P10721; 2 sequenced antibodies.
DR   Antibodypedia; 1392; 5502 antibodies from 56 providers.
DR   DNASU; 3815; -.
DR   Ensembl; ENST00000288135.6; ENSP00000288135.6; ENSG00000157404.17. [P10721-1]
DR   Ensembl; ENST00000687295.1; ENSP00000509450.1; ENSG00000157404.17. [P10721-2]
DR   GeneID; 3815; -.
DR   KEGG; hsa:3815; -.
DR   MANE-Select; ENST00000288135.6; ENSP00000288135.6; NM_000222.3; NP_000213.1.
DR   UCSC; uc010igr.4; human. [P10721-1]
DR   CTD; 3815; -.
DR   DisGeNET; 3815; -.
DR   GeneCards; KIT; -.
DR   HGNC; HGNC:6342; KIT.
DR   HPA; ENSG00000157404; Tissue enhanced (breast).
DR   MalaCards; KIT; -.
DR   MIM; 154800; phenotype.
DR   MIM; 164920; gene.
DR   MIM; 172800; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 601626; phenotype.
DR   MIM; 606764; phenotype.
DR   neXtProt; NX_P10721; -.
DR   OpenTargets; ENSG00000157404; -.
DR   Orphanet; 566393; Acute mast cell leukemia.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 98829; Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22).
DR   Orphanet; 102724; Acute myeloid leukemia with t(8;21)(q22;q22) translocation.
DR   Orphanet; 280785; Bullous diffuse cutaneous mastocytosis.
DR   Orphanet; 566396; Chronic mast cell leukemia.
DR   Orphanet; 79455; Cutaneous mastocytoma.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 158778; Isolated bone marrow mastocytosis.
DR   Orphanet; 158772; Nodular urticaria pigmentosa.
DR   Orphanet; 2884; Piebaldism.
DR   Orphanet; 158769; Plaque-form urticaria pigmentosa.
DR   Orphanet; 280794; Pseudoxanthomatous diffuse cutaneous mastocytosis.
DR   Orphanet; 544260; Selection of therapeutic option in melanoma.
DR   Orphanet; 158775; Smoldering systemic mastocytosis.
DR   Orphanet; 98849; Systemic mastocytosis with associated hematologic neoplasm.
DR   Orphanet; 90389; Telangiectasia macularis eruptiva perstans.
DR   Orphanet; 842; Testicular seminomatous germ cell tumor.
DR   Orphanet; 158766; Typical urticaria pigmentosa.
DR   PharmGKB; PA30128; -.
DR   VEuPathDB; HostDB:ENSG00000157404; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000155626; -.
DR   HOGENOM; CLU_000288_49_0_1; -.
DR   InParanoid; P10721; -.
DR   OMA; KSSAYFN; -.
DR   OrthoDB; 236292at2759; -.
DR   PhylomeDB; P10721; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P10721; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors.
DR   Reactome; R-HSA-9669914; Dasatinib-resistant KIT mutants.
DR   Reactome; R-HSA-9669917; Imatinib-resistant KIT mutants.
DR   Reactome; R-HSA-9669921; KIT mutants bind TKIs.
DR   Reactome; R-HSA-9669924; Masitinib-resistant KIT mutants.
DR   Reactome; R-HSA-9669926; Nilotinib-resistant KIT mutants.
DR   Reactome; R-HSA-9669929; Regorafenib-resistant KIT mutants.
DR   Reactome; R-HSA-9669933; Signaling by kinase domain mutants of KIT.
DR   Reactome; R-HSA-9669934; Sunitinib-resistant KIT mutants.
DR   Reactome; R-HSA-9669935; Signaling by juxtamembrane domain KIT mutants.
DR   Reactome; R-HSA-9669936; Sorafenib-resistant KIT mutants.
DR   Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants.
DR   Reactome; R-HSA-9680187; Signaling by extracellular domain mutants of KIT.
DR   SignaLink; P10721; -.
DR   SIGNOR; P10721; -.
DR   BioGRID-ORCS; 3815; 9 hits in 1106 CRISPR screens.
DR   ChiTaRS; KIT; human.
DR   EvolutionaryTrace; P10721; -.
DR   GeneWiki; CD117; -.
DR   GenomeRNAi; 3815; -.
DR   Pharos; P10721; Tclin.
DR   PRO; PR:P10721; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P10721; protein.
DR   Bgee; ENSG00000157404; Expressed in lateral nuclear group of thalamus and 191 other tissues.
DR   Genevisible; P10721; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002020; F:protease binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0042169; F:SH2 domain binding; IEA:Ensembl.
DR   GO; GO:0005020; F:stem cell factor receptor activity; IEA:Ensembl.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; IBA:GO_Central.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0050910; P:detection of mechanical stimulus involved in sensory perception of sound; ISS:UniProtKB.
DR   GO; GO:0048565; P:digestive tract development; ISS:UniProtKB.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0038162; P:erythropoietin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0038093; P:Fc receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008354; P:germ cell migration; IEA:Ensembl.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IBA:GO_Central.
DR   GO; GO:0035701; P:hematopoietic stem cell migration; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0002327; P:immature B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl.
DR   GO; GO:0038109; P:Kit signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030032; P:lamellipodium assembly; ISS:UniProtKB.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0002551; P:mast cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0043303; P:mast cell degranulation; IMP:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; ISS:UniProtKB.
DR   GO; GO:0070662; P:mast cell proliferation; TAS:UniProtKB.
DR   GO; GO:0035855; P:megakaryocyte development; ISS:UniProtKB.
DR   GO; GO:0097326; P:melanocyte adhesion; ISS:UniProtKB.
DR   GO; GO:0030318; P:melanocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0097324; P:melanocyte migration; ISS:UniProtKB.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0051093; P:negative regulation of developmental process; IEA:Ensembl.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:2000242; P:negative regulation of reproductive process; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; ISS:UniProtKB.
DR   GO; GO:0043473; P:pigmentation; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IBA:GO_Central.
DR   GO; GO:1904343; P:positive regulation of colon smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0002732; P:positive regulation of dendritic cell cytokine production; ISS:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0032765; P:positive regulation of mast cell cytokine production; IDA:UniProtKB.
DR   GO; GO:0070668; P:positive regulation of mast cell proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; TAS:UniProtKB.
DR   GO; GO:0031274; P:positive regulation of pseudopodium assembly; IEA:Ensembl.
DR   GO; GO:0120072; P:positive regulation of pyloric antrum smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB.
DR   GO; GO:1904349; P:positive regulation of small intestine smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB.
DR   GO; GO:1905065; P:positive regulation of vascular associated smooth muscle cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:1904251; P:regulation of bile acid metabolic process; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; ISS:UniProtKB.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   GO; GO:0048863; P:stem cell differentiation; ISS:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; TAS:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043586; P:tongue development; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   DisProt; DP02247; -.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR027263; SCGF_receptor.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PIRSF; PIRSF500951; SCGF_recepter; 1.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane; Cytoplasm;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..976
FT                   /note="Mast/stem cell growth factor receptor Kit"
FT                   /id="PRO_0000016754"
FT   TOPO_DOM        26..524
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        525..545
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        546..976
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          27..112
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          121..205
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          212..308
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          317..410
FT                   /note="Ig-like C2-type 4"
FT   DOMAIN          413..507
FT                   /note="Ig-like C2-type 5"
FT   DOMAIN          589..937
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          568..570
FT                   /note="Important for interaction with phosphotyrosine-
FT                   binding proteins"
FT   ACT_SITE        792
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         568
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT   BINDING         596..603
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         623
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         671..677
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         796
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         797
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT   BINDING         810
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT   SITE            936
FT                   /note="Important for interaction with phosphotyrosine-
FT                   binding proteins"
FT   MOD_RES         547
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:20147452"
FT   MOD_RES         553
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:20147452"
FT   MOD_RES         568
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12824176,
FT                   ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:21030588,
FT                   ECO:0000269|PubMed:9038210"
FT   MOD_RES         570
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12824176,
FT                   ECO:0000269|PubMed:9038210"
FT   MOD_RES         703
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10377264,
FT                   ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:20147452"
FT   MOD_RES         721
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:19265199,
FT                   ECO:0000269|PubMed:20147452, ECO:0000269|PubMed:9038210"
FT   MOD_RES         730
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:20147452"
FT   MOD_RES         741
FT                   /note="Phosphoserine; by PKC/PRKCA"
FT                   /evidence="ECO:0000269|PubMed:7539802"
FT   MOD_RES         746
FT                   /note="Phosphoserine; by PKC/PRKCA"
FT                   /evidence="ECO:0000269|PubMed:7539802"
FT   MOD_RES         821
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:7539802"
FT   MOD_RES         823
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:20147452"
FT   MOD_RES         891
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12878163"
FT   MOD_RES         900
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12878163,
FT                   ECO:0000269|PubMed:20147452"
FT   MOD_RES         936
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10377264,
FT                   ECO:0000269|PubMed:19265199"
FT   MOD_RES         959
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:7539802,
FT                   ECO:0007744|PubMed:19369195"
FT   CARBOHYD        130
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:17662946"
FT   CARBOHYD        145
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        283
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17662946"
FT   CARBOHYD        293
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17662946"
FT   CARBOHYD        300
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17662946"
FT   CARBOHYD        320
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17662946"
FT   CARBOHYD        352
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17662946"
FT   CARBOHYD        367
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17662946"
FT   CARBOHYD        463
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        486
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        58..97
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:17662946"
FT   DISULFID        136..186
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:17662946"
FT   DISULFID        151..183
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:17662946"
FT   DISULFID        233..290
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:17662946"
FT   DISULFID        428..491
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:17662946"
FT   VAR_SEQ         1..744
FT                   /note="MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGD
FT                   EIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFV
FT                   RDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGI
FT                   MIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEF
FT                   TVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVF
FT                   MCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQ
FT                   WIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFN
FT                   VYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSS
FT                   GPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTP
FT                   LLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWE
FT                   FPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELK
FT                   VLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAA
FT                   LYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRI -> MSLPLSFPFLTF
FT                   MVVIAKKNPLFLT (in isoform 3)"
FT                   /id="VSP_060976"
FT   VAR_SEQ         510..513
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:20658618, ECO:0000303|Ref.7"
FT                   /id="VSP_038385"
FT   VARIANT         451
FT                   /note="S -> C (in MASTC; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:24289326"
FT                   /id="VAR_081062"
FT   VARIANT         532
FT                   /note="V -> I (in dbSNP:rs55792975)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042021"
FT   VARIANT         533
FT                   /note="A -> D (in MASTC; unknown pathological significance;
FT                   dbSNP:rs753212327)"
FT                   /evidence="ECO:0000269|PubMed:15173254"
FT                   /id="VAR_081063"
FT   VARIANT         541
FT                   /note="M -> L (in dbSNP:rs3822214)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:19865100"
FT                   /id="VAR_042022"
FT   VARIANT         541
FT                   /note="M -> V (in dbSNP:rs3822214)"
FT                   /id="VAR_061289"
FT   VARIANT         550..558
FT                   /note="Missing (in GIST; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:15824741,
FT                   ECO:0000269|PubMed:9438854"
FT                   /id="VAR_033124"
FT   VARIANT         550
FT                   /note="K -> I (in GIST; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9438854"
FT                   /id="VAR_033123"
FT   VARIANT         551..555
FT                   /note="Missing (in GIST; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9438854"
FT                   /id="VAR_033125"
FT   VARIANT         559..560
FT                   /note="Missing (in GIST; somatic mutation;
FT                   dbSNP:rs121913685)"
FT                   /evidence="ECO:0000269|PubMed:9438854"
FT                   /id="VAR_033128"
FT   VARIANT         559
FT                   /note="V -> A (in GIST; dbSNP:rs121913517)"
FT                   /evidence="ECO:0000269|PubMed:11505412"
FT                   /id="VAR_033126"
FT   VARIANT         559
FT                   /note="V -> D (in GIST; somatic mutation;
FT                   dbSNP:rs121913517)"
FT                   /evidence="ECO:0000269|PubMed:9438854"
FT                   /id="VAR_033127"
FT   VARIANT         559
FT                   /note="Missing (in GIST; dbSNP:rs121913685)"
FT                   /evidence="ECO:0000269|PubMed:9697690"
FT                   /id="VAR_007965"
FT   VARIANT         583
FT                   /note="E -> K (in PBT; dbSNP:rs121913680)"
FT                   /evidence="ECO:0000269|PubMed:1376329"
FT                   /id="VAR_004104"
FT   VARIANT         584
FT                   /note="F -> C (in PBT; dbSNP:rs28933371)"
FT                   /evidence="ECO:0000269|PubMed:11074500"
FT                   /id="VAR_033129"
FT   VARIANT         584
FT                   /note="F -> L (in PBT; dbSNP:rs794726671)"
FT                   /evidence="ECO:0000269|PubMed:1370874"
FT                   /id="VAR_004105"
FT   VARIANT         601
FT                   /note="G -> R (in PBT)"
FT                   /evidence="ECO:0000269|PubMed:11074500"
FT                   /id="VAR_033130"
FT   VARIANT         656
FT                   /note="L -> P (in PBT)"
FT                   /evidence="ECO:0000269|PubMed:11074500"
FT                   /id="VAR_033131"
FT   VARIANT         664
FT                   /note="G -> R (in PBT; dbSNP:rs121913679)"
FT                   /evidence="ECO:0000269|PubMed:1717985"
FT                   /id="VAR_004106"
FT   VARIANT         691
FT                   /note="C -> S (in dbSNP:rs35200131)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042023"
FT   VARIANT         715
FT                   /note="S -> N (in dbSNP:rs56094246)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042024"
FT   VARIANT         737
FT                   /note="D -> N (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs751005114)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042025"
FT   VARIANT         791
FT                   /note="R -> G (in PBT)"
FT                   /evidence="ECO:0000269|PubMed:7687267"
FT                   /id="VAR_004107"
FT   VARIANT         796
FT                   /note="R -> G (in PBT; with sensorineural deafness;
FT                   dbSNP:rs121913684)"
FT                   /evidence="ECO:0000269|PubMed:9450866"
FT                   /id="VAR_033132"
FT   VARIANT         804
FT                   /note="R -> W (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs145602440)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042026"
FT   VARIANT         812
FT                   /note="G -> V (in PBT)"
FT                   /evidence="ECO:0000269|PubMed:7687267"
FT                   /id="VAR_004108"
FT   VARIANT         816
FT                   /note="D -> F (in MASTC; sporadic case; somatic mutation;
FT                   requires 2 nucleotide substitutions; constitutively
FT                   activated and is much more rapidly autophosphorylated than
FT                   wild type)"
FT                   /evidence="ECO:0000269|PubMed:9990072"
FT                   /id="VAR_033133"
FT   VARIANT         816
FT                   /note="D -> H (in a testicular tumor; seminoma; somatic
FT                   mutation; constitutively activated; dbSNP:rs121913506)"
FT                   /evidence="ECO:0000269|PubMed:10362788,
FT                   ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:20147452"
FT                   /id="VAR_033134"
FT   VARIANT         816
FT                   /note="D -> I (in MASTC; somatic mutation; constitutively
FT                   activated; requires 2 nucleotide substitutions;
FT                   dbSNP:rs1057519709)"
FT                   /evidence="ECO:0000269|PubMed:19865100"
FT                   /id="VAR_081064"
FT   VARIANT         816
FT                   /note="D -> V (in MASTSYS, MASTC and mast cell leukemia;
FT                   somatic mutation; constitutively activated; loss of
FT                   interaction with MPDZ; dbSNP:rs121913507)"
FT                   /evidence="ECO:0000269|PubMed:11018522,
FT                   ECO:0000269|PubMed:17595334, ECO:0000269|PubMed:19164557,
FT                   ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:19865100,
FT                   ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7691885,
FT                   ECO:0000269|PubMed:9990072"
FT                   /id="VAR_004109"
FT   VARIANT         816
FT                   /note="D -> Y (in MASTSYS and MASTC; also found in acute
FT                   myeloid leukemia and a germ cell tumor of the testis;
FT                   somatic mutation; constitutively activated;
FT                   dbSNP:rs121913506)"
FT                   /evidence="ECO:0000269|PubMed:16175573,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19865100,
FT                   ECO:0000269|PubMed:9657776, ECO:0000269|PubMed:9990072"
FT                   /id="VAR_023828"
FT   VARIANT         820
FT                   /note="D -> G (in mast cell disease; systemic;
FT                   dbSNP:rs121913682)"
FT                   /evidence="ECO:0000269|PubMed:9029028"
FT                   /id="VAR_033135"
FT   VARIANT         822
FT                   /note="N -> I (in MASTC; constitutively activated;
FT                   dbSNP:rs993022333)"
FT                   /evidence="ECO:0000269|PubMed:21689725"
FT                   /id="VAR_081065"
FT   VARIANT         822
FT                   /note="N -> K (in a germ cell tumor of the testis; somatic
FT                   mutation; dbSNP:rs121913514)"
FT                   /evidence="ECO:0000269|PubMed:16175573,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_023829"
FT   VARIANT         829
FT                   /note="A -> P (in a germ cell tumor of the testis; somatic
FT                   mutation; dbSNP:rs1057519713)"
FT                   /evidence="ECO:0000269|PubMed:16175573,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_023830"
FT   VARIANT         839
FT                   /note="E -> K (in MASTC; sporadic case; somatic mutation;
FT                   dominant negative mutation; loss of autophosphorylation;
FT                   dbSNP:rs121913509)"
FT                   /evidence="ECO:0000269|PubMed:9990072"
FT                   /id="VAR_033136"
FT   VARIANT         847
FT                   /note="T -> P (in PBT; dbSNP:rs121913687)"
FT                   /evidence="ECO:0000269|PubMed:9699740"
FT                   /id="VAR_033137"
FT   VARIANT         893..896
FT                   /note="Missing (in PBT; severe)"
FT                   /evidence="ECO:0000269|PubMed:8680409"
FT                   /id="VAR_004110"
FT   MUTAGEN         381
FT                   /note="R->A: Reduces autophosphorylation in response to
FT                   KITLG/SCF."
FT                   /evidence="ECO:0000269|PubMed:17662946"
FT   MUTAGEN         386
FT                   /note="E->A: Reduces autophosphorylation in response to
FT                   KITLG/SCF."
FT                   /evidence="ECO:0000269|PubMed:17662946"
FT   MUTAGEN         571
FT                   /note="I->A: Reduction in SH2B2/APS binding. Abolishes
FT                   SH2B2/APS binding; when associated with A-939."
FT                   /evidence="ECO:0000269|PubMed:12444928"
FT   MUTAGEN         623
FT                   /note="K->M: Stronger interaction with MPDZ."
FT                   /evidence="ECO:0000269|PubMed:11018522"
FT   MUTAGEN         741
FT                   /note="S->A: Abolishes down-regulation of kinase activity
FT                   by PKC/PRKCA-mediated phosphorylation; when associated with
FT                   A-746."
FT                   /evidence="ECO:0000269|PubMed:7539802"
FT   MUTAGEN         746
FT                   /note="S->A: Abolishes down-regulation of kinase activity
FT                   by PKC/PRKCA-mediated phosphorylation; when associated with
FT                   A-741."
FT                   /evidence="ECO:0000269|PubMed:7539802"
FT   MUTAGEN         823
FT                   /note="Y->F: No decrease in activity. Leads to
FT                   autophosphorylation at Tyr-900."
FT                   /evidence="ECO:0000269|PubMed:20147452"
FT   MUTAGEN         939
FT                   /note="L->A: Reduction in SH2B2/APS binding. Abolishes
FT                   SH2B2/APS binding; when associated with A-571."
FT                   /evidence="ECO:0000269|PubMed:12444928"
FT   CONFLICT        764
FT                   /note="L -> I (in Ref. 10; AAH71593)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        838
FT                   /note="P -> H (in Ref. 10; AAH71593)"
FT                   /evidence="ECO:0000305"
FT   STRAND          38..41
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          44..47
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          54..59
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          63..72
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          75..77
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          79..86
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   HELIX           89..91
FT                   /evidence="ECO:0007829|PDB:2E9W"
FT   STRAND          93..99
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          104..110
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          125..130
FT                   /evidence="ECO:0007829|PDB:2E9W"
FT   STRAND          132..134
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          146..149
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          151..153
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          161..165
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   TURN            166..168
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          169..174
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          183..188
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          193..200
FT                   /evidence="ECO:0007829|PDB:2E9W"
FT   STRAND          203..205
FT                   /evidence="ECO:0007829|PDB:2E9W"
FT   STRAND          213..215
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          219..224
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          229..239
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          243..248
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          258..263
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          265..267
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          269..279
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   TURN            282..284
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          286..293
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          298..310
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          312..319
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          321..325
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          331..341
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          344..350
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          356..364
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          367..369
FT                   /evidence="ECO:0007829|PDB:2EC8"
FT   STRAND          372..379
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   HELIX           384..386
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          388..395
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          400..409
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          411..420
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   HELIX           422..424
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          425..434
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          437..444
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          445..449
FT                   /evidence="ECO:0007829|PDB:4PGZ"
FT   STRAND          452..454
FT                   /evidence="ECO:0007829|PDB:4PGZ"
FT   STRAND          458..462
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          465..468
FT                   /evidence="ECO:0007829|PDB:4PGZ"
FT   STRAND          472..479
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   HELIX           481..483
FT                   /evidence="ECO:0007829|PDB:4PGZ"
FT   STRAND          485..494
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   STRAND          499..506
FT                   /evidence="ECO:0007829|PDB:4K94"
FT   HELIX           550..552
FT                   /evidence="ECO:0007829|PDB:7KHG"
FT   STRAND          558..564
FT                   /evidence="ECO:0007829|PDB:3G0E"
FT   STRAND          567..570
FT                   /evidence="ECO:0007829|PDB:3G0E"
FT   TURN            573..575
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           580..582
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           586..588
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          589..597
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          599..613
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          617..625
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           627..629
FT                   /evidence="ECO:0007829|PDB:6HH1"
FT   HELIX           631..647
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          656..660
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          662..665
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          667..671
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          674..677
FT                   /evidence="ECO:0007829|PDB:7KHK"
FT   HELIX           678..684
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   TURN            685..688
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          719..721
FT                   /evidence="ECO:0007829|PDB:2IUH"
FT   HELIX           754..756
FT                   /evidence="ECO:0007829|PDB:4HVS"
FT   STRAND          757..759
FT                   /evidence="ECO:0007829|PDB:4HVS"
FT   HELIX           760..762
FT                   /evidence="ECO:0007829|PDB:4HVS"
FT   HELIX           766..785
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          788..790
FT                   /evidence="ECO:0007829|PDB:3G0F"
FT   HELIX           795..797
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          798..801
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   TURN            802..804
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          805..808
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           812..814
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           817..819
FT                   /evidence="ECO:0007829|PDB:3G0E"
FT   STRAND          823..825
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          827..831
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           833..835
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           838..843
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           848..863
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   TURN            864..866
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   STRAND          869..872
FT                   /evidence="ECO:0007829|PDB:6ITT"
FT   HELIX           877..885
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           897..906
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           911..913
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   HELIX           917..930
FT                   /evidence="ECO:0007829|PDB:1T46"
FT   TURN            931..933
FT                   /evidence="ECO:0007829|PDB:1T45"
SQ   SEQUENCE   976 AA;  109865 MW;  81B0CD76817F3454 CRC64;
     MRGARGAWDF LCVLLLLLRV QTGSSQPSVS PGEPSPPSIH PGKSDLIVRV GDEIRLLCTD
     PGFVKWTFEI LDETNENKQN EWITEKAEAT NTGKYTCTNK HGLSNSIYVF VRDPAKLFLV
     DRSLYGKEDN DTLVRCPLTD PEVTNYSLKG CQGKPLPKDL RFIPDPKAGI MIKSVKRAYH
     RLCLHCSVDQ EGKSVLSEKF ILKVRPAFKA VPVVSVSKAS YLLREGEEFT VTCTIKDVSS
     SVYSTWKREN SQTKLQEKYN SWHHGDFNYE RQATLTISSA RVNDSGVFMC YANNTFGSAN
     VTTTLEVVDK GFINIFPMIN TTVFVNDGEN VDLIVEYEAF PKPEHQQWIY MNRTFTDKWE
     DYPKSENESN IRYVSELHLT RLKGTEGGTY TFLVSNSDVN AAIAFNVYVN TKPEILTYDR
     LVNGMLQCVA AGFPEPTIDW YFCPGTEQRC SASVLPVDVQ TLNSSGPPFG KLVVQSSIDS
     SAFKHNGTVE CKAYNDVGKT SAYFNFAFKG NNKEQIHPHT LFTPLLIGFV IVAGMMCIIV
     MILTYKYLQK PMYEVQWKVV EEINGNNYVY IDPTQLPYDH KWEFPRNRLS FGKTLGAGAF
     GKVVEATAYG LIKSDAAMTV AVKMLKPSAH LTEREALMSE LKVLSYLGNH MNIVNLLGAC
     TIGGPTLVIT EYCCYGDLLN FLRRKRDSFI CSKQEDHAEA ALYKNLLHSK ESSCSDSTNE
     YMDMKPGVSY VVPTKADKRR SVRIGSYIER DVTPAIMEDD ELALDLEDLL SFSYQVAKGM
     AFLASKNCIH RDLAARNILL THGRITKICD FGLARDIKND SNYVVKGNAR LPVKWMAPES
     IFNCVYTFES DVWSYGIFLW ELFSLGSSPY PGMPVDSKFY KMIKEGFRML SPEHAPAEMY
     DIMKTCWDAD PLKRPTFKQI VQLIEKQISE STNHIYSNLA NCSPNRQKPV VDHSVRINSV
     GSTASSSQPL LVHDDV
//
